InvestorsHub Logo

Lorie3168

03/06/22 12:42 PM

#448917 RE: Lorie3168 #448916

Those question marks after Ukraine were supposed to be sunflowers. Guess that doesn’t show up as a graphic.

exwannabe

03/06/22 12:48 PM

#448919 RE: Lorie3168 #448916

This LADY [LP] has balls of steal


Agree with you 100%.

Not the first to use bio-bucks to set up a CDMO. But the first to do it twice, and in companies owned by her, not the dev stage bio pouring the cash in.

FeMike has nothing on LP.

Sojourner55

03/06/22 2:33 PM

#448933 RE: Lorie3168 #448916

Nicely said Lorie. Agree.

HappyLibrarian

03/06/22 2:57 PM

#448937 RE: Lorie3168 #448916

Perfectionists often fail to get things done because they cannot accept the good enough. That would explain a lot of what has gone wrong here.

marzan

03/06/22 3:17 PM

#448940 RE: Lorie3168 #448916

Agreed! If LP is not this steadfast, personalized cell therapy vaccine using DC cells that is perfected and targeted and commercially produced would never take place on this planet. Only LP could do it and she is of course making it possible that we will find out in a few weeks, imo.

survivor1x

03/06/22 5:52 PM

#448964 RE: Lorie3168 #448916

I keep getting reminded year after year from one of the of the long term survivors pushing the envelope in this trial. Almost pushing a decade at this point. Each year I see the post of the "1 more year". This person is not one of the well known patients on twitter. They are not known on this board.

biosectinvestor

03/06/22 6:08 PM

#448966 RE: Lorie3168 #448916

Well said, and yes, it can take many, many years to get new technology from out of the lab, into trials and then at a level where it can be manufactured commercially and is approvable. It can take multiple decades and does. That is not unique to this company or DCVax. LP seems to have studied the landscape well and understands the failures of other companies and is navigating this technology, it seems to me, to put it in the post possible position to succeed. And that is good not just for patients in the long-run, but also for patient shareholders. All IMHO.